Comparative effectiveness of plasma-derived and recombinant FVIII concentrates in the on-demand and prophylactic treatment of patients with haemophilia A [2]

Haemophilia

Volumn 10, Issue 5, 2004, Pages 676-678

  Pollmann, H ^a   Richter, H ^a   Siegmund, B ^a  

^a Inst fur Thromb Hamostaseologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; HAEMOCTIN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTHROPATHY; BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; GERMANY; HEMOPHILIA A; HOME CARE; HUMAN; LETTER; PRIORITY JOURNAL;

FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; PLASMA; RECURRENCE; TREATMENT OUTCOME;

EID: 4844228004     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.00949.x     Document Type: Letter

References (13)

1. Mannucci PM. Hemophilia and related bleeding disorders: a story of dismay and success. Hematology (Am Soc Hematol Educ Program) 2002; 1: 1-9.
2. Suiter TM. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely? Semin Thromb Hemost 2002; 28: 277-83.
3. Shapiro AD. A global view on prophylaxis: possibilities and consequences. Haemophilia 2003; 9(Suppl. 1): 10-7.
4. White GC II, Courter S, Bray GL, Lee M, Gomperts ED, The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
5. Aygoren-Pursun E, Scharrer I, German Kogenate Study Group. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost 1997; 78: 1352-6.
6. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, for The Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of inhibitors. N Engl J Med 1993; 328: 453-9.
7. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
8. Seremetis S, Lusher JM, Abildgaard CF et al. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 1999; 5: 9-16.
9. Kelly KM, Butler RB, Farace L, Cohen AR, Manno CS. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A. J Pediatr 1997; 130: 537-40.
10. Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002; 8: 76-82.
11. Van Den Berg HM, Fischer K, Van Der Bom JG, Roosendaal G, Mauser-Bunschoten EP. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002; 8(Suppl. 2): 43-6.
12. Aledort LM, Haschmeyer RH, Pettersson H, The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
13. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 158(Suppl. 3): S166-70.